The clinical and economic burden of chronic obstructive pulmonary disease in the USA.
TLDR
With more than 50 new medications in the pipeline for the treatment of COPD, optimal management will continue to evolve and grow more complex as benefits of therapy are balanced with the limitations and needs of each patient.Abstract:
Chronic obstructive pulmonary disease (COPD) is the third most common cause of death in the USA. In 2010, the cost of COPD in the USA was projected to be approximately US$50 billion, which includes $20 billion in indirect costs and $30 billion in direct health care expenditures. These costs can be expected to continue to rise with this progressive disease. Costs increase with increasing severity of disease, and hospital stays account for the majority of these costs. Patients are diagnosed with COPD following a multifactorial assessment that includes spirometry, clinical presentation, symptomatology, and risk factors. Smoking cessation interventions are the most influential factor in COPD management. The primary goal of chronic COPD management is stabilization of chronic disease and prevention of acute exacerbations. Bronchodilators are the mainstay of COPD therapy. Patients with few symptoms and low exacerbation risk should be treated with a short-acting bronchodilator as needed for breathlessness. Progression of symptoms, as well as possible decline in forced expiratory volume in the first second of expiration (FEV1), warrant the use of long-acting bronchodilators. For patients with frequent exacerbations with or without consistent symptoms, inhaled corticosteroids should be considered in addition to a long-acting beta2-agonist (LABA) or long-acting muscarinic antagonist (LAMA) and may even consist of "triple therapy" with all three agents with more severe disease. Phosphodiesterase-4 inhibitors may be an option in patients with frequent exacerbations and symptoms of chronic bronchitis. In addition to a variety of novel ultra-LABAs, LAMAs and combination bronchodilator and inhaled corticosteroid (ICS) therapies, other bronchodilators with a variety of mechanisms are also being considered, to expand therapeutic options for the treatment of COPD. With more than 50 new medications in the pipeline for the treatment of COPD, optimal management will continue to evolve and grow more complex as benefits of therapy are balanced with the limitations and needs of each patient.read more
Citations
More filters
Journal ArticleDOI
Pulmonary rehabilitation for chronic obstructive pulmonary disease
TL;DR: In four important domains of quality of life (QoL) (Chronic Respiratory Questionnaire (CRQ) scores for dyspnoea, fatigue, emotional function and mastery), the effect was larger than the minimal clinically important difference (MCID) of 0.4%.
Journal ArticleDOI
Total and State-Specific Medical and Absenteeism Costs of COPD Among Adults Aged ≥ 18 Years in the United States for 2010 and Projections Through 2020
TL;DR: Evidence-based interventions that prevent tobacco use and reduce the clinical complications of COPD may result in potential decreased COPD-attributable costs, which are projected to increase through 2020.
Journal ArticleDOI
Respiration rate and volume measurements using wearable strain sensors.
Michael Chu,Thao Nguyen,Vaibhav Pandey,Yongxiao Zhou,Hoang N. Pham,Ronen Bar-Yoseph,Shlomit Radom-Aizik,Ramesh Jain,Dan M. Cooper,Michelle Khine +9 more
TL;DR: A wearable sensor capable of simultaneously measuring both respiration rate and volume with high fidelity is introduced, and it is demonstrated that both metrics are highly correlated to measurements from a medical grade continuous spirometer on participants at rest.
Journal ArticleDOI
An official American Thoracic Society/European Respiratory Society statement: research questions in COPD
Bartolome R. Celli,Marc Decramer,Jadwiga A. Wedzicha,Kevin C. Wilson,Alvar Agusti,Gerard J. Criner,William MacNee,Barry J. Make,Stephen I. Rennard,Robert A. Stockley,Claus Vogelmeier,Antonio Anzueto,David H. Au,Peter J. Barnes,Pierre-Régis Burgel,Peter M. Calverley,Ciro Casanova,Enrico Clini,Christopher B. Cooper,Harvey O. Coxson,Daniel Dusser,Leonardo M. Fabbri,Bonnie Fahy,Gary T. Ferguson,Andrew M. Fisher,Monica Fletcher,Maurice Hayot,John R. Hurst,Paul Jones,Donald A. Mahler,François Maltais,David M. Mannino,Fernando J. Martinez,Marc Miravitlles,Paula Meek,Alberto Papi,Klaus F. Rabe,Nicolas Roche,Frank C. Sciurba,Sanjay Sethi,Nikos M. Siafakas,Don D. Sin,Joan B. Soriano,James K. Stoller,Donald P. Tashkin,Thierry Troosters,Geert Verleden,Johny Verschakelen,Jørgen Vestbo,John W. Walsh,George R. Washko,Robert A. Wise,Emiel F.M. Wouters,Richard ZuWallack +53 more
TL;DR: Recommendations for research that addresses important gaps in the evidence in all areas of COPD were formulated via discussion and consensus, and the types of research that leading clinicians, researchers, and patient advocates believe will have the greatest impact on patient-centred outcomes were highlighted.
Journal ArticleDOI
Economic Burden of Chronic Obstructive Pulmonary Disease (COPD): A Systematic Literature Review.
TL;DR: Moderate-to-very severe COPD represents a considerable economic burden for healthcare providers despite the availability of efficacious treatments and comprehensive guidelines on their use.
References
More filters
Journal ArticleDOI
Computed Tomography — An Increasing Source of Radiation Exposure
David J. Brenner,Eric J. Hall +1 more
TL;DR: The facts are summarized about CT scans, which involve much higher doses of radiation than plain films, and the implications for public health are summarized.
Journal ArticleDOI
Rehospitalizations among Patients in the Medicare Fee-for-Service Program
TL;DR: Rehospitalizations among Medicare beneficiaries are prevalent and costly and about 10% of rehospitalizations were likely to have been planned.
Journal ArticleDOI
Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease.
Julie A. Anderson,Bartolome R. Celli,Gary T. Ferguson,Christine Jenkins,Paul W. Jones,Julie C. Yates,Jørgen Vestbo +6 more
TL;DR: The reduction in death from all causes among patients with COPD in the combination-therapy group did not reach the predetermined level of statistical significance, and there were significant benefits in all other outcomes among these patients.
Journal ArticleDOI
Susceptibility to Exacerbation in Chronic Obstructive Pulmonary Disease
John R. Hurst,Jørgen Vestbo,Jørgen Vestbo,Antonio Anzueto,Nicholas Locantore,Hana Müllerová,Ruth Tal-Singer,Bruce E. Miller,David A. Lomas,Alvar Agusti,William MacNee,Peter M.A. Calverley,Stephen I. Rennard,Emiel F.M. Wouters,Jadwiga A. Wedzicha +14 more
TL;DR: Although exacerbations become more frequent and more severe as COPD progresses, the rate at which they occur appears to reflect an independent susceptibility phenotype, which has implications for the targeting of exacerbation-prevention strategies across the spectrum of disease severity.
Journal ArticleDOI
Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease
TL;DR: The MRC dyspnoea scale is a simple and valid method of categorising patients with COPD in terms of their disability that could be used to complement FEV1 in the classification of COPD severity.
Related Papers (5)
Susceptibility to Exacerbation in Chronic Obstructive Pulmonary Disease
Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010
Rafael Lozano,Mohsen Naghavi,Kyle J Foreman,Stephen S Lim,Kenji Shibuya,Victor Aboyans,Jerry Abraham,Tim Adair,Rakesh Aggarwal,Stephanie Y. Ahn,Mohammad A. AlMazroa,Miriam Alvarado,H. Ross Anderson,Laurie M. Anderson,Kathryn G. Andrews,Charles Atkinson,Larry M. Baddour,Suzanne Barker-Collo,David Bartels,Michelle L. Bell,Emelia J. Benjamin,Derrick A Bennett,Kavi Bhalla,Boris Bikbov,Aref A. Bin Abdulhak,Gretchen L. Birbeck,Fiona M. Blyth,Ian Bolliger,Soufiane Boufous,Chiara Bucello,Michael Burch,Peter Burney,Jonathan R. Carapetis,Honglei Chen,David Chou,Sumeet S. Chugh,Luc E. Coffeng,Steven D. Colan,Samantha M. Colquhoun,K. Ellicott Colson,John R. Condon,Myles Connor,Myles Connor,Leslie T. Cooper,Matthew A. Corriere,Monica Cortinovis,Karen Courville De Vaccaro,William G. Couser,Benjamin C Cowie,Michael H. Criqui,Marita Cross,Kaustubh Dabhadkar,Nabila Dahodwala,Diego De Leo,Louisa Degenhardt,Allyne Delossantos,Julie O. Denenberg,Don C. Des Jarlais,Samath D Dharmaratne,Samath D Dharmaratne,E. Ray Dorsey,Tim Driscoll,Herbert C. Duber,Beth E. Ebel,Patricia J. Erwin,Patricia Espindola,Majid Ezzati,Valery L. Feigin,Abraham D. Flaxman,Mohammad H. Forouzanfar,F.G.R. Fowkes,Richard C. Franklin,Marlene Fransen,Michael Freeman,Sherine E. Gabriel,Emmanuela Gakidou,Flavio Gaspari,Richard F. Gillum,Diego Gonzalez-Medina,Yara A. Halasa,Diana Haring,James Harrison,Rasmus Havmoeller,Rasmus Havmoeller,Roderick J. Hay,Bruno Hoen,Peter J. Hotez,Damian G Hoy,Kathryn H. Jacobsen,Spencer L. James,Rashmi Jasrasaria,Sudha Jayaraman,Nicole E. Johns,Ganesan Karthikeyan,Nicholas J Kassebaum,Andre Keren,Jon Paul Khoo,Lisa M. Knowlton,Olive Kobusingye,Adofo Koranteng,Rita Krishnamurthi,Michael S Lipnick,Steven E. Lipshultz,Summer Lockett Ohno,Jacqueline Mabweijano,Jacqueline Mabweijano,Michael F. Macintyre,Leslie Mallinger,Lyn March,Guy B. Marks,Robin Marks,Akira Matsumori,Richard Matzopoulos,Richard Matzopoulos,Bongani M. Mayosi,John H. McAnulty,Mary M. McDermott,John J. McGrath,Ziad A. Memish,George A. Mensah,Tony R. Merriman,Catherine Michaud,Matthew J. Miller,Ted R. Miller,Charles Mock,Ana Olga Mocumbi,Ali A. Mokdad,Andrew E. Moran,Kim Mulholland,M. Nathan Nair,Luigi Naldi,K.M. Venkat Narayan,Kiumarss Nasseri,Paul Norman,Martin O'Donnell,Saad B. Omer,Katrina F Ortblad,Richard H. Osborne,Doruk Ozgediz,Bishnu Pahari,Jeyaraj D Pandian,Andrea Panozo Rivero,Rogelio Perez Padilla,Fernando Perez-Ruiz,Norberto Perico,David Phillips,Kelsey Pierce,C. Arden Pope,Esteban Porrini,Farshad Pourmalek,Murugesan Raju,Dharani Ranganathan,Jürgen Rehm,David B. Rein,G. Remuzzi,Frederick P. Rivara,Thomas Roberts,Felipe Rodriguez De Leòn,Lisa C. Rosenfeld,Lesley Rushton,Ralph L. Sacco,Joshua A. Salomon,Uchechukwu Sampson,Ella Sanman,David C. Schwebel,Maria Segui-Gomez,Donald S. Shepard,David Singh,Jessica Singleton,Karen Sliwa,Emma Smith,Andrew C Steer,Jennifer A. Taylor,Bernadette Thomas,Imad M. Tleyjeh,Jeffrey A. Towbin,Thomas Truelsen,Eduardo A. Undurraga,Narayanaswamy Venketasubramanian,Lakshmi Vijayakumar,Theo Vos,Gregory R. Wagner,Mengru Wang,Wenzhi Wang,Kerrianne Watt,Martin A. Weinstock,Robert G. Weintraub,James D. Wilkinson,Anthony D. Woolf,Sarah Wulf,Pon Hsiu Yeh,Paul S. F. Yip,Azadeh Zabetian,Zhi Jie Zheng,Alan D. Lopez,Christopher J L Murray +195 more